Monogenic disease therapy developer Lexeo Therapeutics has publicly launched with financing from backers including Lundbeckfonden Ventures.
US-based gene therapy developer Lexeo Therapeutics has emerged from stealth with an oversubscribed $85m series A round featuring Lundbeckfonden Ventures, the strategic investment arm of pharmaceutical firm Lundbeck.
The round was co-led by healthcare-focused venture capital firm Longitude Capital and investment firm Omega Funds and included life sciences real estate investment trust Alexandria Real Estate Equities’ VC unit, Alexandria Venture Investments.
Non-profit research organisation Alzheimer’s Drug Discovery Foundation, PBM Capital, Janus Henderson Investors, Invus and Woodline Partners also contributed to…
